News

PPD is expecting that the offices will strengthen its full range of drug discovery and development services and continue to position it to capitalise on the growth of

The MAA was withdrawn following communication from the Committee for Medicinal Products for Human Use (CHMP) of the EMA citing a major objection. The major objection noted that

The consolidation of DSP’s two North American businesses serves to solidify DSP’s North American operations into one combined center of excellence. The unification of DSPA and Sepracor brings

Hematide, a synthetic, peptide-based erythropoiesis-stimulating agent (ESA), is designed to act on the erythropoietin receptors and stimulate the production of red blood cells by dosing once every four

The study investigated the use of GM-CSF (granulocyte/macrophage colony-stimulating factor) as an adjuvant with the DNA prime for the GeoVax DNA/MVA vaccine for prevention of HIV/AIDS. The National

The CHMP has recommended the marketing authorisation of Humenza vaccine in EU countries for the active immunisation of persons 6 months of age and older against influenza disease

FDA priority review status is granted to therapies that offer major advances in treatment or provide a treatment where no adequate therapy exists. This status accelerates the standard

In the study, 1,000 healthy volunteers aged 18 to 64 years old were enrolled to receive two doses of 5mcg, 15mcg or 45mcg of Novavax’s 2009 H1N1 influenza

Horizant is an investigational treatment for moderate-to-severe primary Restless Legs Syndrome developed by Xenoport and licensed to GlaxoSmithKline. Depomed noted that unlike Horizant, its proprietary extended release formulations